Bristol-Myers Squibb Co. (NYSE: BMY)’s stock price has dropped by -0.16 in relation to previous closing price of 51.40. Nevertheless, the company has seen a loss of -5.37% in its stock price over the last five trading days. Reuters reported 2024-04-06 that Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.
Is It Worth Investing in Bristol-Myers Squibb Co. (NYSE: BMY) Right Now?
The price-to-earnings ratio for Bristol-Myers Squibb Co. (NYSE: BMY) is 13.30x, which is above its average ratio. Moreover, the 36-month beta value for BMY is 0.40. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 11 as “hold,” and 2 as “sell.”
The public float for BMY is 2.02B and currently, short sellers hold a 1.84% of that float. On April 08, 2024, BMY’s average trading volume was 16.45M shares.
BMY’s Market Performance
The stock of Bristol-Myers Squibb Co. (BMY) has seen a -5.37% decrease in the past week, with a -3.86% drop in the past month, and a -1.38% fall in the past quarter. The volatility ratio for the week is 1.70%, and the volatility levels for the past 30 days are at 1.85% for BMY. The simple moving average for the last 20 days is -2.59% for BMY’s stock, with a simple moving average of -7.26% for the last 200 days.
Analysts’ Opinion of BMY
Redburn Atlantic, on the other hand, stated in their research note that they expect to see BMY reach a price target of $54, previously predicting the price at $77. The rating they have provided for BMY stocks is “Neutral” according to the report published on February 06th, 2024.
BofA Securities gave a rating of “Neutral” to BMY, setting the target price at $60 in the report published on January 03rd of the current year.
BMY Trading at 0.50% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.78% of loss for the given period.
Volatility was left at 1.85%, however, over the last 30 days, the volatility rate increased by 1.70%, as shares sank -3.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.15% upper at present.
During the last 5 trading sessions, BMY fell by -5.37%, which changed the moving average for the period of 200-days by -22.28% in comparison to the 20-day moving average, which settled at $52.59. In addition, Bristol-Myers Squibb Co. saw 0.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $49.78 back on Dec 05 ’23. After this action, BOERNER CHRISTOPHER S. now owns 82,672 shares of Bristol-Myers Squibb Co., valued at $99,560 using the latest closing price.
BOERNER CHRISTOPHER S., the Chief Executive Officer of Bristol-Myers Squibb Co., purchase 3,071 shares at $48.86 during a trade that took place back on Nov 28 ’23, which means that BOERNER CHRISTOPHER S. is holding 79,384 shares at $150,049 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.76 for the gross margin
The net margin for Bristol-Myers Squibb Co. stands at 0.18. The total capital return value is set at 0.18. Equity return is now at value 26.53, with 8.36 for asset returns.
Based on Bristol-Myers Squibb Co. (BMY), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at 0.33. The debt to equity ratio resting at 1.41. The interest coverage ratio of the stock is 11.06.
Currently, EBITDA for the company is 19.18 billion with net debt to EBITDA at 1.66. When we switch over and look at the enterprise to sales, we see a ratio of 2.97. The receivables turnover for the company is 2.95for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
To wrap up, the performance of Bristol-Myers Squibb Co. (BMY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
